Multiple Myeloma Hub

57 Episoade

1. How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease

   Publicat: 08.07.2020
2. Melphalan flufenamide (melflufen) + novel agents for RRMM

   Publicat: 08.07.2020
3. Isatuximab plus KRd for high-risk NDMM

   Publicat: 24.06.2020
4. Novel approaches in multiple myeloma: what is unique about CELMoDs?

   Publicat: 24.06.2020
5. Hot topics in MM: quadruplets and anti-BCMA therapy

   Publicat: 24.06.2020
6. Genomics of high-risk myeloma

   Publicat: 23.06.2020
7. The association between the diversity of the oral microbiome and PFS

   Publicat: 22.06.2020
8. Novel approaches in multiple myeloma: BFCR4350A

   Publicat: 18.06.2020
9. Update from CARTITUDE-1 | What's new since ASH?

   Publicat: 08.06.2020
10. Novel approaches in multiple myeloma: TAK-079

    Publicat: 04.06.2020
11. Should we use KRd or VRd for patients with NDMM?

    Publicat: 04.06.2020
12. What is the optimal treatment for bone lesions, including patients with renal insufficiency?

    Publicat: 03.06.2020
13. Recent advances in our understanding of myeloma progression

    Publicat: 02.06.2020
14. Quadruplet combinations in transplant-ineligible NDMM: isatuximab + Vd + cyclo or len

    Publicat: 01.06.2020
15. How I treat elderly patients with NDMM

    Publicat: 28.05.2020
16. Understanding resistance mechanisms to current standard of care and how to overcome them

    Publicat: 19.05.2020
17. What is plasma cell leukemia and what are the latest advances in treatment?

    Publicat: 15.05.2020